APLS (Apellis Pharmaceuticals, Inc.) Stock Financials & Earnings

APLSApellis Pharmaceuticals, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$1.0B

Net Income (TTM)$22M

EPS (TTM)$0.17

Free Cash Flow (TTM)$45M

Gross Margin89.8%

Op. Margin5.5%

Net Margin2.2%

FCF Margin4.5%

P/S Ratio (TTM)2.5x

P/E Ratio (TTM)112.7x

YoY Rev Growth+28.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$45M	$37M	-$175M
Q2 23	$95M	$87M	-$120M
Q3 23	$110M	$88M	-$137M
Q4 23	$146M	$126M	-$85M
Q1 24	$172M	$152M	-$62M
Q2 24	$200M	$176M	-$29M
Q3 24	$197M	$163M	-$47M
Q4 24	$213M	$172M	-$26M
Q1 25	$167M	$132M	-$83M
Q2 25	$178M	$164M	-$33M
Q3 25	$459M	$434M	$223M
Q4 25	$200M	$170M	-$51M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$110M	$102M	—	—
Q2 23	$96M	$111M	—	—
Q3 23	$79M	$146M	—	—
Q4 23	$69M	$142M	—	—
Q1 24	$85M	—	—	$129M
Q2 24	$78M	—	—	$128M
Q3 24	$89M	—	—	$122M
Q4 24	$76M	$38M	$83M	—
Q1 25	$86M	—	—	$129M
Q2 25	$67M	—	—	$131M
Q3 25	$68M	—	—	$143M
Q4 25	$74M	—	—	$147M

Revenue Segments

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$765M	$0	$765M
Q2 23	$616M	$9M	$626M
Q3 23	$452M	$13M	$466M
Q4 23	$351M	$1M	$352M
Q1 24	$327M	$0	$327M
Q2 24	$360M	$8M	$368M
Q3 24	$397M	$0	$397M
Q4 24	$411M	$5M	$416M
Q1 25	$358M	$0	$358M
Q2 25	$371M	$0	$371M
Q3 25	$479M	$0	$479M
Q4 25	$468M	$0	$468M

Shares Outstanding

Revenue Per Employee

Revenue / Employee